Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. Extended-release capsules are indicated to induce remission of mild to moderate ulcerative colitis and a rectal foam is used for mild to moderate distal ulcerative colitis. In addition, a delayed-release capsule formulation of budesonide is indicated to reduce proteinuria in adults with IgA nephropathy at risk of rapid disease progression. In Europe, budesonide is indicated to treat eosinophilic esophagitis (EoE) in adults.
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
Little Lungs Study
- Conditions
- Invasive Mechanical VentilationSevere Respiratory Distress Syndrome
- Interventions
- First Posted Date
- 2025-03-03
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 30
- Registration Number
- NCT06855043
- Locations
- 🇺🇸
Meriter Hospital, Madison, Wisconsin, United States
🇺🇸American Family Children's Hospital, Madison, Wisconsin, United States
Early Screening of Young COPD and Pre-COPD
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2025-02-25
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- yanmengkang
- Target Recruit Count
- 100
- Registration Number
- NCT06844175
Budesonide As a Treatment for Functional Dyspepsia
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 56
- Registration Number
- NCT06841406
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
The Effect of Modified Olfactory Training on Postoperative Olfactory Dysfunction in Patients With CRS
- Conditions
- Olfactory DysfunctionChronic Rhinosinusitis
- Interventions
- Device: Conventional olfactory training deviceDevice: Modified olfactory training device
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 213
- Registration Number
- NCT06837051
- Locations
- 🇨🇳
Beijing, Beijing, Beijing, China
Nasal Obstruction With Oxymetazoline and Corticosteroids
- Conditions
- Nasal Obstruction
- Interventions
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 80
- Registration Number
- NCT06830109
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22369
- Registration Number
- NCT06744374
- Locations
- 🇺🇸
AstraZeneca, Wilmington, Delaware, United States
EXACERBATIONS AND REAL-WORLD OUTOMES INCLUDING CARDIOPULMONARY EVENTS AMONG PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (MITOS: EROS+CP US Study)
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13000
- Registration Number
- NCT06742736
- Locations
- 🇺🇸
AstraZeneca, Wilmington, Delaware, United States
Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum
- Conditions
- Crohn Disease (CD)
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 114
- Registration Number
- NCT06719622
- Locations
- 🇵🇱
Jagiellonian University, Kraków, Poland
🇵🇱Poznań University of Medical Sciences, Poznań, Poland
🇵🇱Medical University of Warsaw, Warsawa, Poland
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Calliditas Therapeutics AB
- Target Recruit Count
- 60
- Registration Number
- NCT06712407
- Locations
- 🇺🇸
Yale University Nephrology Clinical Trials Program, New Haven, Connecticut, United States
🇺🇸The University of Texas Medical Branch UTMB, Galveston, Texas, United States
🇺🇸Arizona Kidney Disease & Hypertension Centers (AKDHC), Glendale, Arizona, United States
Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2000
- Registration Number
- NCT06712563
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.